Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309985 · ClinicalTrials.gov registry record · Phase 3
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
A Phase 3 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 790
- Enrollment target
NCT00309985: Completed Phase 3 study, sponsored by ECOG-ACRIN Cancer Research Group.
NCT00309985 is a Phase 3 study that has completed, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 790 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00309985, a Phase 3 study, has completed, sponsored by ECOG-ACRIN Cancer Research Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 790 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether androgen-ablation therapy is more effective with or without docetaxel in treating metastatic prostate cancer. PURPOSE: This randomized phase III trial is studying androgen-ablation therapy and chemotherapy to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
Primary Outcome
Overall survival is defined as the time from randomization to death or date last known alive. Survival data reflects the database as of December 23, 2013.
Interventions
- DRUG docetaxel
- DRUG androgen-deprivation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 790 participants |
| Start Date | 2006-09-26 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 3 |
What the finished NCT00309985 record still lists
NCT00309985 is an interventional study that assigns participants to a tested intervention. The registered 790 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00309985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00309985 about?
NCT00309985 is a clinical study titled "Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them fr...
What is the current status of trial NCT00309985?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 790 participants. The study started on 2006-09-26. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT00309985?
The interventions under investigation include: docetaxel (DRUG), androgen-deprivation therapy (DRUG).
Who is sponsoring clinical trial NCT00309985?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00309985's enrollment target sits among peer trials
790 429th of 2000 higher than 1,570 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04967989 · 790 participants · Phase 3
Clarifying the Optimal Application of SLT Therapy Trial
- NCT06162611 · 790 participants · Phase 4
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
- NCT03424005 · 792 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- NCT05866081 · 792 participants · NA
Stent Omission After Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI